PL2913340T3 - Receptor komórek T swoisty wobec antygenu guza Wilmsa - Google Patents

Receptor komórek T swoisty wobec antygenu guza Wilmsa

Info

Publication number
PL2913340T3
PL2913340T3 PL14196412T PL14196412T PL2913340T3 PL 2913340 T3 PL2913340 T3 PL 2913340T3 PL 14196412 T PL14196412 T PL 14196412T PL 14196412 T PL14196412 T PL 14196412T PL 2913340 T3 PL2913340 T3 PL 2913340T3
Authority
PL
Poland
Prior art keywords
cell receptor
tumor antigen
wilms tumor
receptor specific
specific
Prior art date
Application number
PL14196412T
Other languages
English (en)
Inventor
Hans Josef Stauss
Liquan Gao
Shao-An Xue
Original Assignee
Imperial Innovations Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Limited filed Critical Imperial Innovations Limited
Publication of PL2913340T3 publication Critical patent/PL2913340T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4242Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243Wilms tumor 1 [WT1]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/10041Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14196412T 2003-12-06 2004-12-06 Receptor komórek T swoisty wobec antygenu guza Wilmsa PL2913340T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0328363.7A GB0328363D0 (en) 2003-12-06 2003-12-06 Therapeutically useful molecules
EP14196412.2A EP2913340B1 (en) 2003-12-06 2004-12-06 T cell receptor specific for wilms tumour antigen
EP04805928.1A EP1692172B1 (en) 2003-12-06 2004-12-06 T cell receptor specific for wilms tumour antigen

Publications (1)

Publication Number Publication Date
PL2913340T3 true PL2913340T3 (pl) 2019-02-28

Family

ID=30129780

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14196412T PL2913340T3 (pl) 2003-12-06 2004-12-06 Receptor komórek T swoisty wobec antygenu guza Wilmsa

Country Status (7)

Country Link
US (4) US7951783B2 (pl)
EP (3) EP3115374B1 (pl)
DK (1) DK2913340T3 (pl)
ES (2) ES2689926T3 (pl)
GB (1) GB0328363D0 (pl)
PL (1) PL2913340T3 (pl)
WO (1) WO2005056595A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
WO2007100568A2 (en) * 2006-02-24 2007-09-07 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US7820174B2 (en) 2006-02-24 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services T cell receptors and related materials and methods of use
GB0917094D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
MX2013011363A (es) * 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
CA2884366A1 (en) * 2012-09-12 2014-03-20 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
US11203783B2 (en) 2013-11-21 2021-12-21 Repertoire Genesis Incorporation T cell receptor and B cell receptor repertoire analysis system, and use of same in treatment and diagnosis
KR102415259B1 (ko) * 2013-11-22 2022-06-30 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 조작된 고-친화도의 인간 t 세포 수용체
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
US20190048085A1 (en) 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy
JP7328211B2 (ja) * 2017-04-24 2023-08-16 オスペダーレ サン ラファエレ エス.アール.エル Tcr及びペプチド
JP2020523985A (ja) * 2017-05-31 2020-08-13 科済生物医薬(上海)有限公司Carsgen Therapeutics Co.,Ltd. 細胞免疫治療の組成物及び方法
KR20250037592A (ko) 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf CHIMERIC ANTIGEN RECEPTORS
GB201817821D0 (en) * 2018-10-31 2018-12-19 Ospedale San Raffaele Srl TCR and peptides
WO2020185796A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
JP7737978B2 (ja) * 2019-08-20 2025-09-11 フレッド ハッチンソン キャンサー センター Wt-1に特異的なt細胞免疫療法
WO2021097325A1 (en) * 2019-11-14 2021-05-20 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5610031A (en) * 1993-10-27 1997-03-11 The General Hospital Corporation B1k chain of laminin and methods of use
US6028169A (en) * 1997-03-31 2000-02-22 Human Genome Sciences, Inc. Chemokine β-6 antagonists
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
US6770749B2 (en) * 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
ATE475669T1 (de) * 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen

Also Published As

Publication number Publication date
ES2689926T3 (es) 2018-11-16
WO2005056595A3 (en) 2005-10-06
EP1692172A2 (en) 2006-08-23
EP2913340A1 (en) 2015-09-02
US7951783B2 (en) 2011-05-31
DK2913340T3 (en) 2018-10-22
US20110274675A1 (en) 2011-11-10
EP3115374A1 (en) 2017-01-11
US9732141B2 (en) 2017-08-15
HK1214280A1 (en) 2016-07-22
US20070191496A1 (en) 2007-08-16
US10450360B2 (en) 2019-10-22
EP2913340B1 (en) 2018-07-04
EP1692172B1 (en) 2015-02-11
US20160340404A1 (en) 2016-11-24
GB0328363D0 (en) 2004-01-14
WO2005056595A2 (en) 2005-06-23
EP3115374B1 (en) 2022-01-19
ES2534224T3 (es) 2015-04-20
US20150147302A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
PL2913340T3 (pl) Receptor komórek T swoisty wobec antygenu guza Wilmsa
NO20071430L (no) Anti-OX4OL antistoffer
DK1599504T3 (da) Modificeret antistof
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
IL179891A0 (en) Tumor specific antibody
NO20044347L (no) Anti-alfavbeta6-antistoff
HUS1500037I1 (hu) IL-17 antagonista antitestek
EP1616881A4 (en) ANTI-MPL ANTIBODY
EP1693385A4 (en) HUMANIZED ANTI-CD47 ANTIBODY
DE602004016995D1 (de) In-situ gelierendes arzneimittelabgabesystem
DE602004022855D1 (de) Interleukin-10-antikörper
IS8596A (is) Mótefni gegn CD154
EP1712519A4 (en) REFORMER
DE60322351D1 (de) Reaktionszelle
ITRE20030073A1 (it) Antenna planare monostrato.
DK2171060T3 (da) Superagonistisk anti-CD28-antistof
FI20040970A0 (fi) Laitteisto solujen kuvaamiseksi
NO20044109D0 (no) Stromskinne-holdeanordning
EP1682512A4 (en) Immunohistochemical methods
GB0401876D0 (en) New use for cancer antigen
DE502004008433D1 (de) Wägezelle
NO20033082L (no) Enkeltcelleproteinmateriale
NO20044145L (no) Assay for anti-INGAP antistoffer
GB0306618D0 (en) Antibody
DE60319020D1 (de) Verbessertes geldannahmegerät